Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 21, 623-625 (2022)
doi: https://doi.org/10.1038/d41573-022-00139-6
Updates & Corrections
-
Correction 18 August 2022: The text has been updated to reflect that phase III trials of deucravacitinib for systemic lupus erythematosus are planned rather than ongoing, and to clarify the role of Celgene in the development of NDI-034858.